Impact of metformin on anti-Mullerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial

被引：11

作者：

Madsen, Helen N. ^{[1
]}

Lauszus, Finn F. ^{[2
]}

Trolle, Birgitta ^{[3
]}

Ingerslev, Hans J. ^{[3
]}

Torring, Niels ^{[1
]}

机构：

[1] Aarhus Univ Hosp, Dept Clin Biochem, DK-8200 Skejby N, Aarhus, Denmark

[2] Herning Hosp, Dept Obstet & Gynecol, Herning, Denmark

[3] Aarhus Univ Hosp, Dept Obstet & Gynecol, DK-8200 Skejby N, Aarhus, Denmark

来源：

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA | 2015年 / 94卷 / 05期

关键词：

Anti-Mullerian hormone; Mullerian inhibiting substance; polycystic ovary syndrome; metformin; randomized controlled trial;

D O I：

10.1111/aogs.12605

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Conclusions on the effect of metformin on circulating anti-Mullerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS) are ambiguous. We performed a secondary analysis of a randomized, double-blind, placebo-controlled cross-over trial. Fifty-six women with hyperandrogenemic PCOS were included. Each woman served as her own control receiving a daily dose of either 1700mg metformin or placebo for 6months. After a 3-month wash-out period they received the opposite treatment. The decrease in AMH from a median of 49.5 to 46.9pmol/L after 6months on metformin was overall not significant (p=0.81), nor were changes in obese women (from 49.5 to 38.2pmol/L; p=0.53). Comparing individual metformin/placebo AMH values, a small absolute decrease of 9.3pmol/L (p=0.03) was observed in obese women after 6months relative to baseline, suggesting a trend towards decreasing values after metformin treatment, mainly in obese women.

引用

页码：547 / 551

页数：5

共 12 条

[1] Anti-Mullerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome [J].

Carlsen, S. M. ;

Vanky, E. ;

Fleming, R. .

HUMAN REPRODUCTION, 2009, 24 (07) :1732-1738

[2] Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome [J].

Diamanti-Kandarakis, Evanthia ;

Christakou, Charikleia D. ;

Kandaraki, Eleni ;

Economou, Frangiskos N. .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2010, 162 (02) :193-212

[3] Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment [J].

Fleming, R ;

Harborne, L ;

MacLaughlin, DT ;

Ling, D ;

Norman, J ;

Sattar, N ;

Seifer, DB .

FERTILITY AND STERILITY, 2005, 83 (01) :130-136

[4] Effects of metformin on serum insulin and anti-mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome [J].

Nascimento, Areana Diogo ;

Silva Lara, Lucia Alves ;

Japur de Sa Rosa-e-Silva, Ana Carolina ;

Ferriani, Rui Alberto ;

Reis, Rosana Maria .

GYNECOLOGICAL ENDOCRINOLOGY, 2013, 29 (03) :246-249

[5] Polycystic ovary syndrome [J].

Norman, Robert J. ;

Dewailly, Didier ;

Legro, Richard S. ;

Hickey, Theresa E. .

LANCET, 2007, 370 (9588) :685-697

[6] The impact of oral contraceptives and metformin on anti-Mullerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia [J].

Panidis, Dimitrios ;

Georgopoulos, Neoklis A. ;

Piouka, Athanasia ;

Katsikis, Ilias ;

Saltamavros, Alexandros D. ;

Decavalas, George ;

Diamanti-Kandarakis, Evanthia .

GYNECOLOGICAL ENDOCRINOLOGY, 2011, 27 (08) :587-592

[7] Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries [J].

Pellatt, Laura ;

Hanna, Laurine ;

Brincat, Mark ;

Galea, Ray ;

Brain, Henrietta ;

Whitehead, Saffron ;

Mason, Helen .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (01) :240-245

[8] Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: Relationship to the ovarian follicle excess and to the follicular arrest [J].

Pigny, P ;

Merlen, E ;

Robert, Y ;

Cortet-Rudelli, C ;

Decanter, C ;

Jonard, S ;

Dewailly, D .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (12) :5957-5962

[9] Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome [J].

Piltonen, T ;

Morin-Papunen, L ;

Koivunen, R ;

Perheentupa, A ;

Ruokonen, A ;

Tapanainen, JS .

HUMAN REPRODUCTION, 2005, 20 (07) :1820-1826

[10] The Metabolic Status Modulates the Effect of Metformin on the Antimullerian Hormone-Androgens-Insulin Interplay in Obese Women with Polycystic Ovary Syndrome [J].

Romualdi, D. ;

De Cicco, S. ;

Tagliaferri, V. ;

Proto, C. ;

Lanzone, A. ;

Guido, M. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (05) :E821-E824

← 1 2 →